FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215714718> ?p ?o ?g. }

• W3215714718 abstract "Chronic lymphocytic leukemia (CLL) is the most common leukemia in the USA, affecting predominantly older adults. CLL is characterized by low physical fitness, reduced immunity, and increased risk of secondary malignancies and infections. One approach to improving CLL patients' physical fitness and immune functions may be participation in a structured exercise program. The aims of this pilot study were to examine physical and immunological changes, and feasibility of a 12-week high-intensity interval training (HIIT) combined with muscle endurance-based resistance training on older adults with treatment naïve CLL. We enrolled eighteen participants with CLL aged 64.9 ± 9.1 years and assigned them to groups depending on distance lived from our fitness center. Ten participants (4 M/6F) completed HIIT and six participants (4 M/2F) completed a non-exercising control group (Controls). HIIT consisted of three 30-min treadmill sessions/week plus two concurrent 30-min strength training sessions/week. Physical and immunological outcomes included aerobic capacity, muscle strength and endurance, and natural killer (NK) cell recognition and killing of tumor cells. We confirmed feasibility if > 70% of HIIT participants completed > 75% of prescribed sessions and prescribed minutes, and if > 80% of high-intensity intervals were at a heart rate corresponding to at least 80% of peak aerobic capacity (VO2peak). Results are presented as Hedge's G effect sizes (g), with 0.2, 0.5 and 0.8 representing small, medium and large effects, respectively. Following HIIT, leg strength (g = 2.52), chest strength (g = 1.15) and seated row strength (g = 3.07) were 35.4%, 56.1% and 39.5% higher than Controls, respectively, while aerobic capacity was 3.8% lower (g = 0.49) than Controls. Similarly, following HIIT, in vitro NK-cell cytolytic activity against the K562 cell line (g = 1.43), OSU-CLL cell line (g = 0.95), and autologous B-cells (g = 1.30) were 20.3%, 3.0% and 14.6% higher than Controls, respectively. Feasibility was achieved, with HIIT completing 5.0 ± 0.2 sessions/week and 99 ± 3.6% of the prescribed minutes/week at heart rates corresponding to 89 ± 2.8% of VO2peak. We demonstrate that 12-weeks of supervised HIIT combined with muscle endurance-based resistance training is feasible, and that high adherence and compliance are associated with large effects on muscle strength and immune function in older adults with treatment naïve CLL.Trial registration: NCT04950452." @default.
• W3215714718 created "2021-12-06" @default.
• W3215714718 creator A5005090839 @default.
• W3215714718 creator A5026057093 @default.
• W3215714718 creator A5029711312 @default.
• W3215714718 creator A5042332348 @default.
• W3215714718 creator A5062061907 @default.
• W3215714718 creator A5063333779 @default.
• W3215714718 creator A5067645481 @default.
• W3215714718 creator A5083401032 @default.
• W3215714718 creator A5089744206 @default.
• W3215714718 date "2021-11-30" @default.
• W3215714718 modified "2023-10-13" @default.
• W3215714718 title "A pilot study of high-intensity interval training in older adults with treatment naïve chronic lymphocytic leukemia" @default.
• W3215714718 cites W1599119377 @default.
• W3215714718 cites W1747288778 @default.
• W3215714718 cites W1964085099 @default.
• W3215714718 cites W1966631052 @default.
• W3215714718 cites W1977013960 @default.
• W3215714718 cites W1995928801 @default.
• W3215714718 cites W1997483664 @default.
• W3215714718 cites W1998517969 @default.
• W3215714718 cites W2017405165 @default.
• W3215714718 cites W2031811366 @default.
• W3215714718 cites W2054499416 @default.
• W3215714718 cites W2059527510 @default.
• W3215714718 cites W2069612491 @default.
• W3215714718 cites W2078249396 @default.
• W3215714718 cites W2091028596 @default.
• W3215714718 cites W2093220633 @default.
• W3215714718 cites W2110825257 @default.
• W3215714718 cites W2112998032 @default.
• W3215714718 cites W2120992267 @default.
• W3215714718 cites W2122644128 @default.
• W3215714718 cites W2143293793 @default.
• W3215714718 cites W2151299033 @default.
• W3215714718 cites W2152193038 @default.
• W3215714718 cites W2176427838 @default.
• W3215714718 cites W2295349524 @default.
• W3215714718 cites W2317888977 @default.
• W3215714718 cites W2430283214 @default.
• W3215714718 cites W2609271578 @default.
• W3215714718 cites W2621247331 @default.
• W3215714718 cites W2737584748 @default.
• W3215714718 cites W2790385276 @default.
• W3215714718 cites W2792485109 @default.
• W3215714718 cites W2808027513 @default.
• W3215714718 cites W2886723159 @default.
• W3215714718 cites W2945986090 @default.
• W3215714718 cites W2948314199 @default.
• W3215714718 cites W2953984817 @default.
• W3215714718 cites W2981263606 @default.
• W3215714718 cites W2990804434 @default.
• W3215714718 cites W2993123216 @default.
• W3215714718 cites W3008233889 @default.
• W3215714718 cites W3013505851 @default.
• W3215714718 cites W3018966504 @default.
• W3215714718 cites W3021342411 @default.
• W3215714718 cites W3162070108 @default.
• W3215714718 cites W36729050 @default.
• W3215714718 cites W4235474157 @default.
• W3215714718 cites W4242371861 @default.
• W3215714718 cites W93303826 @default.
• W3215714718 doi "https://doi.org/10.1038/s41598-021-02352-6" @default.
• W3215714718 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8633014" @default.
• W3215714718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34848750" @default.
• W3215714718 hasPublicationYear "2021" @default.
• W3215714718 type Work @default.
• W3215714718 sameAs 3215714718 @default.
• W3215714718 citedByCount "6" @default.
• W3215714718 countsByYear W32157147182022 @default.
• W3215714718 countsByYear W32157147182023 @default.
• W3215714718 crossrefType "journal-article" @default.
• W3215714718 hasAuthorship W3215714718A5005090839 @default.
• W3215714718 hasAuthorship W3215714718A5026057093 @default.
• W3215714718 hasAuthorship W3215714718A5029711312 @default.
• W3215714718 hasAuthorship W3215714718A5042332348 @default.
• W3215714718 hasAuthorship W3215714718A5062061907 @default.
• W3215714718 hasAuthorship W3215714718A5063333779 @default.
• W3215714718 hasAuthorship W3215714718A5067645481 @default.
• W3215714718 hasAuthorship W3215714718A5083401032 @default.
• W3215714718 hasAuthorship W3215714718A5089744206 @default.
• W3215714718 hasBestOaLocation W32157147181 @default.
• W3215714718 hasConcept C103038586 @default.
• W3215714718 hasConcept C121332964 @default.
• W3215714718 hasConcept C126322002 @default.
• W3215714718 hasConcept C171687745 @default.
• W3215714718 hasConcept C1862650 @default.
• W3215714718 hasConcept C2777938653 @default.
• W3215714718 hasConcept C2777973682 @default.
• W3215714718 hasConcept C2778461978 @default.
• W3215714718 hasConcept C2781444488 @default.
• W3215714718 hasConcept C2781464450 @default.
• W3215714718 hasConcept C2992361435 @default.
• W3215714718 hasConcept C62520636 @default.
• W3215714718 hasConcept C71924100 @default.
• W3215714718 hasConcept C93038891 @default.
• W3215714718 hasConceptScore W3215714718C103038586 @default.
• W3215714718 hasConceptScore W3215714718C121332964 @default.
• W3215714718 hasConceptScore W3215714718C126322002 @default.

• next